ERBB2 and neoplasm: In a very recent work, Kristensen et al. reported the effect of site-specific labeling on the stability, immuno-reactivity, and tumor-targeting properties of trastuzumab and they compared it to conventional random labeling on Lys residues in a HER2-positive xenograft mouse model [144].